Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study
(2009)
Journal Article
Dueland, S., Aamdal, S., Lind, M. J., Thomas, H., Sandvold, M. L., Gaullier, J.-M., & Rasch, W. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica, 48(1), 137-145. https://doi.org/10.1080/02841860802183620
Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More about Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study.